Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial.

ABSTRACT:

Background

Indolent systemic mastocytosis is a clonal mast cell disease that results in an increase in mast cells in the skin, bone marrow, and other organ systems. IL-6 has been shown to promote mast cell maturation, proliferation, and reactivity in vitro. Serum levels of IL-6 correlate with severity of disease and risk of progression of systemic disease.

Objective

We conducted a double-blind placebo-controlled study to assess safety and efficacy for the use of sarilumab in improving the quality of life for those with indolent systemic mastocytosis. ClinicalTrial.gov registration NCT03770273.

Methods

A double-blind trial randomized 16 participants. The primary analysis compared the arms on the Mastocytosis Quality of Life Questionnaire (MC-QoL) index at 16 wee

SUBMITTER: Komarow HD 

PROVIDER: S-EPMC12172267 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature